Physician profile
Shahid Ali
NPI 1881604460
$7,316.67
in general payments reported to CMS, 2019-2025
36 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $1,243 · 2021: $1,566 · 2022: $845 · 2023: $658 · 2024: $751 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.57 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,878.89 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $746.65 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $741.63 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $604.36 | 2019-2025 | |
| Boston Scientific Corporation | $409.73 | 2019-2025 | Exalt Model D |
| Celgene Corporation | $389.42 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $338.54 | 2020-2023 | Linzess |
| Alkermes, INC. | $295.75 | 2020 | |
| Redhill Biopharma INC. | $268.21 | 2021-2023 | Talicia |
| Pfizer INC. | $171.52 | 2024-2025 | |
| Janssen Biotech, INC. | $154.02 | 2020-2025 | Simponi, Remicade, Stelara |
| Madrigal Pharmaceuticals | $149.04 | 2025 | Rezdiffra |
| Medtronic, INC. | $138.56 | 2025 | Nexpowder |
| Novo Nordisk INC | $121.85 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $110.01 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $103.74 | 2019-2023 | Sutab |
| Impulse Dynamics (USA) INC. | $86.60 | 2021 | |
| Romark Laboratories, Lc | $79.08 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.27 | 2020 | |
| Intercept Pharmaceuticals, INC. | $51.33 | 2019-2020 | |
| Celltrion USA INC. | $47.77 | 2024-2025 | Vegzelma |
| Pharmacosmos Therapeutics INC. | $47.26 | 2021 | |
| Allergan, INC. | $45.69 | 2019 | |
| Shire North American Group INC | $42.32 | 2019 | |
| Merck Sharp & Dohme LLC | $36.27 | 2020-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $30.42 | 2024 | Voquezna |
| Cumberland Pharmaceuticals, INC. | $27.90 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.62 | 2021 | |
| Ardelyx, INC. | $22.95 | 2022 | |
| Lilly USA, LLC | $19.40 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $17.79 | 2025 | Zenpep |
| Conmed Corporation | $15.56 | 2019 | |
| Echosens North America, INC. | $14.75 | 2025 | Fibroscan |
| Cook Medical LLC | $11.77 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,834.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahid Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.